MEM

MEMPHASYS FPO [MEM]
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Healthcare · ASX Small Cap
$0.0080 +0.0%

Updated 22 Jul 2026 · Signals refresh every scan

⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Get alerts when MEM triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track MEM — Free

Active Signals

Bullish Signals

  • Trading above both moving averages — the trend is your friend here
  • Beating the Small Ords index — relative strength of 1.40, so it's outpacing the pack
  • Trading above the 200-day average — the long-term trend is on your side
  • Critical cash runway (0.6 quarters)
  • 4C filed 2026-07-15
  • Very high P/S ratio (115.4x)
  • Revenue in sharp decline (-96%)
  • Near 52-week high (91% of range)
  • Small-cap ($20-100M)
  • New substantial holder(s) (1)
  • CANSLIM N: Near 52-week high (breakout territory)
  • Sentiment is mixed — no strong consensus either way
  • Positive long-term momentum — up 33% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (5.92%/day)
  • Altman Z-Score grey zone (2.99, low-confidence approx)
  • Penny stock risk ($0.008)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 1d (+5pts)

Risk Signals

  • Piotroski F-Score weak (2/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -96% — the top line is shrinking
Ask Scout AI about MEM
"What's driving MEM today?" "How does MEM compare to peers?" "Key risks for MEM?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW Quarterly Activities/Appendix 4C Cash Flow Report
HIGH Becoming a substantial holder
NONE Memphasys Enters into Consulting Agreement with Director
NONE Exclusive Thailand Commercialisation Agreement Secured
NONE Section 708A Cleansing Statement

Recent ASX Announcements

2026-07-15 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE
2026-07-15 Becoming a substantial holder
2026-07-06 Memphasys Enters into Consulting Agreement with Director
2026-06-30 Exclusive Thailand Commercialisation Agreement Secured PRICE SENSITIVE
2026-06-26 Section 708A Cleansing Statement

Key Metrics

$24.7M
Market Cap
6.5M
Avg Volume
0.4x
Vol Ratio
$0.00 — $0.01
52-Week Range
N/A
Short Interest
1 qtrs
Cash Runway
-87.4%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / CatalystspassNear 52w High
SSupply & DemandneutralFloat: 53%
LLeader vs LaggardpassRS: 30
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:MEM vs IDTMEM vs ADRMEM vs LDX
Scout Pro — Deeper Analysis for MEM
Try Pro free for 30 days
Share this analysis

Track MEM and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required